Provention Bio(PRVB)盘前暴涨超260% 赛诺菲(SNY)将以每股25美元现金收购该公司

金吾资讯2023-03-13

Provention Bio(PRVB)盘前暴涨超260%，报24.13美元。Provention Bio与赛诺菲(SNY)已达成协议，赛诺菲已同意以每股25.00美元的现金收购Provention Bio，Inc。相当于约29亿美元的股权价值。该交易为赛诺菲在普通药物方面的核心资产组合增加了一项创新的、完全拥有的、一流的1型糖尿病疗法，并进一步推动其向差异化产品的战略转变。去年，TZIELD (...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2319881056?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2023-03-13 17:46","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2319881056","market":"us","top_or_hot":-1,"title":"Provention Bio(PRVB)盘前暴涨超260% 赛诺菲(SNY)将以每股25美元现金收购该公司","media":"金吾资讯","content":"<div>\n<p>Provention Bio(PRVB)盘前暴涨超260%，报24.13美元。Provention Bio与赛诺菲(SNY)已达成协议，赛诺菲已同意以每股25.00美元的现金收购Provention Bio，Inc。相当于约29亿美元的股权价值。该交易为赛诺菲在普通药物方面的核心资产组合增加了一项创新的、完全拥有的、一流的1型糖尿病疗法，并进一步推动其向差异化产品的战略转变。去年，TZIELD (...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20230313174635826a044c&s=b\">网页链接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Provention Bio(PRVB)盘前暴涨超260% 赛诺菲(SNY)将以每股25美元现金收购该公司</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nProvention Bio(PRVB)盘前暴涨超260% 赛诺菲(SNY)将以每股25美元现金收购该公司\n</h2>\n\n<h4 class=\"meta\">\n\n\n2023-03-13 17:46 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20230313174635826a044c&s=b><strong>金吾资讯</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Provention Bio(PRVB)盘前暴涨超260%，报24.13美元。Provention Bio与赛诺菲(SNY)已达成协议，赛诺菲已同意以每股25.00美元的现金收购Provention Bio，Inc。相当于约29亿美元的股权价值。该交易为赛诺菲在普通药物方面的核心资产组合增加了一项创新的、完全拥有的、一流的1型糖尿病疗法，并进一步推动其向差异化产品的战略转变。去年，TZIELD (...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20230313174635826a044c&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4007","symbol_name":"制药","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20230313174635826a044c&s=b","article_id":"2319881056","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20230313174635826a044c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2319881056","pubTimestamp":1678700773,"columns":[],"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"Provention Bio盘前暴涨超260%，报24.13美元。Provention Bio与赛诺菲已达成协议，赛诺菲已同意以每股25.00美元的现金收购Provention Bio，Inc。对于赛诺菲来说，此次收购是一次战略上的契合，因为Provention Bio在免疫介导的疾病和高需求领域的疾病缓解疗法方面的增长与其在糖尿病方面的专业知识相结合。此次收购建立在与Provention Bio现有的联合推广协议基础上，proven tion Bio已经将TZIELD提供给需要这种免疫介导疗法的患者。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"BK4007":"制药","PRVB":"Provention Bio, Inc"},"translate_title":"Provention Bio (PRVB) soared by more than 260% before the market. Sanofi (SNY) will acquire the company in cash of $25 per share","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PRVB":0.9},"content_text":"Provention Bio(PRVB)盘前暴涨超260%，报24.13美元。Provention Bio与赛诺菲(SNY)已达成协议，赛诺菲已同意以每股25.00美元的现金收购Provention Bio，Inc。相当于约29亿美元的股权价值。该交易为赛诺菲在普通药物方面的核心资产组合增加了一项创新的、完全拥有的、一流的1型糖尿病疗法，并进一步推动其向差异化产品的战略转变。去年，TZIELD (teplizumab-mzwv)在美国获得批准，成为首个也是唯一一个用于延迟8岁及以上2期1型糖尿病成人和儿童患者3期1型糖尿病(T1D)发病的疗法。对于赛诺菲来说，此次收购是一次战略上的契合，因为Provention Bio在免疫介导的疾病和高需求领域的疾病缓解疗法方面的增长与其在糖尿病方面的专业知识相结合。赛诺菲将继续利用其在糖尿病方面的能力，最大限度地发挥TZIELD作为全球和美国变革性疗法的潜力，旨在为每年约65，000名确诊患者中的部分患者推迟3期1型糖尿病的发作。此次收购建立在与Provention Bio现有的联合推广协议基础上，proven tion Bio已经将TZIELD提供给需要这种免疫介导疗法的患者。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2319881056"}